Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S 26308

Known as: S-26308 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

imiquimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Imiquimod: a cytokine inducer.
  • M. Dahl
  • Journal of the American Academy of Dermatology
  • 2002
    • Corpus ID: 184867
T he articles in this supplement address the use of topically applied imiquimod (Aldara, R-837, S-26308) for the treatment of… Expand
Review
2001
Review
2001
Imiquimod applied topically: A novel immune response modifier.
  • S. Tyring
  • Skin therapy letter
  • 2001
    • Corpus ID: 42004647
Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), and immune response modifier, was approved as… Expand
Highly Cited
1999
Highly Cited
1999
Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod.
Imiquimod (also known as R-837 and S-26308) is an imidazoquinoline immune response modifier and is available in the US and… Expand
Review
1999
Review
1999
Imiquimod applied topically: a novel immune response modifier and new class of drug.
Imiquimod (S-26308, R-837) (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4 amine), an immune response modifier, demonstrates… Expand
Highly Cited
1995
Highly Cited
1995
Cytokine induction by the immunomodulators imiquimod and S‐27609
Imiquimod (R‐837, S‐26308) and the analogue S‐27609 were evaluated for cytokine induction in human blood cells. Both compounds… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE